Unlock stock picks and a broker-level newsfeed that powers Wall Street.
Upgrade Now
NasdaqCM - Nasdaq Real Time Price USD

Hoth Therapeutics, Inc. (HOTH)

Compare
0.9784
+0.0037
+(0.38%)
At close: 4:00:01 PM EDT
0.9400
-0.04
(-3.92%)
After hours: 5:23:16 PM EDT
All All Favorites Text Statistics Technicals Fibonacci Markings Lines
Loading Chart for HOTH

Recent News: HOTH

View More
Hoth Therapeutics Collaborates with Washington University on NIH Grant Application Advancing Alzheimer's Program Using NK-1 Receptor Antagonist HT-ALZ

Hoth Therapeutics Collaborates with Washington University on NIH Grant Application Advancing Alzheimer's Program Using NK-1 Receptor Antagonist HT-ALZ
PR Newswire 9 hours ago
Hoth Therapeutics Announces Positive Pre Clinical Data HT-ALZ Shows Promising Breakthrough in Alzheimer's Disease Research Acute treatment with HT-ALZ led to a rapid (~15%) reduction in brain interstitial fluid Aβ levels, within 20 hours

Hoth Therapeutics Announces Positive Pre Clinical Data HT-ALZ Shows Promising Breakthrough in Alzheimer's Disease Research Acute treatment with HT-ALZ led to a rapid (~15%) reduction in brain interstitial fluid Aβ levels, within 20 hours
PR Newswire 9 hours ago
Hoth Therapeutics Receives USPTO Filing Receipt for HT-001 Formulation Patent Application, Expanding Existing Patent Coverage

Hoth Therapeutics Receives USPTO Filing Receipt for HT-001 Formulation Patent Application, Expanding Existing Patent Coverage
PR Newswire 2 days ago
Hoth Therapeutics Advances Cancer Fighting HT-KIT Program with New Patent Filing and Preclinical Study Initiation

Hoth Therapeutics Advances Cancer Fighting HT-KIT Program with New Patent Filing and Preclinical Study Initiation
PR Newswire 7 days ago
Hoth Therapeutics announces ‘positive’ results from study of HT-KIT

Hoth Therapeutics announces ‘positive’ results from study of HT-KIT
TipRanks 14 days ago
Hoth Therapeutics Announces Positive Preclinical Results for HT-KIT in Aggressive Cancer Gastrointestinal Stromal Tumors (GIST). HT-KIT Triggered Significant Tumor Cell Death as Early as 24 Hours Post-treatment

Hoth Therapeutics Announces Positive Preclinical Results for HT-KIT in Aggressive Cancer Gastrointestinal Stromal Tumors (GIST). HT-KIT Triggered Significant Tumor Cell Death as Early as 24 Hours Post-treatment
PR Newswire 15 days ago
Hoth Therapeutics Announces Plans to Submit Expanded Access Application for HT-001 to Support Cancer Patients in Need

Hoth Therapeutics Announces Plans to Submit Expanded Access Application for HT-001 to Support Cancer Patients in Need
PR Newswire 23 days ago
Hoth Therapeutics Announces Positive Results for HT-001 in Treating EGFR Inhibitor-Associated Papulopustular Eruptions Findings to be Presented at the American Academy of Dermatology 2025 Annual Meeting

Hoth Therapeutics Announces Positive Results for HT-001 in Treating EGFR Inhibitor-Associated Papulopustular Eruptions Findings to be Presented at the American Academy of Dermatology 2025 Annual Meeting
PR Newswire 28 days ago
Hoth Therapeutics Announces Positive Findings on GDNF's Potential as a Game-Changer in Obesity Treatment and Reduced Fatty Liver Disease

Hoth Therapeutics Announces Positive Findings on GDNF's Potential as a Game-Changer in Obesity Treatment and Reduced Fatty Liver Disease
PR Newswire 29 days ago
Hoth Therapeutics Partners with OnTargetx R&D to Advance Research for Cancer fighting HT-KIT Cancer Therapeutic

Hoth Therapeutics Partners with OnTargetx R&D to Advance Research for Cancer fighting HT-KIT Cancer Therapeutic
PR Newswire last month
Hoth Therapeutics Regains Compliance with Nasdaq Listing Requirements

Hoth Therapeutics Regains Compliance with Nasdaq Listing Requirements
PR Newswire 2 months ago
View More

Related Tickers

SONN Sonnet BioTherapeutics Holdings, Inc.
1.3100
+3.15%
 
PHIO Phio Pharmaceuticals Corp.
1.2100
-1.63%
 
CERO CERo Therapeutics Holdings, Inc.
0.7290
+1.25%
 
SLRX Salarius Pharmaceuticals, Inc.
0.7265
+2.48%
 
ONCO Onconetix, Inc.
0.0793
+4.76%
 
PSTV Plus Therapeutics, Inc.
0.8902
-12.73%
 
SNSE Sensei Biotherapeutics, Inc.
0.3660
+5.84%
 
SILO Silo Pharma, Inc.
1.0800
-4.42%
 
RGLS Regulus Therapeutics Inc.
1.9600
+12.00%
 
CNTB Connect Biopharma Holdings Limited
0.6306
+10.21%